Valeant Pharmaceuticals is planning sweeping changes to its board of directors as it moves to set a new tone at the top of a company under fire from politicians and investors for its management and drug-pricing practices.
from WSJ.com: US Business http://ift.tt/1rjeugm
via IFTTT
No comments:
Post a Comment